Objective:To observe the auxiliary curative effect of Combined Clostridium and Bifidobacterium Capsules,Live(also called Changlekang)in the treatment of allergic rhinitis by comparing IL-10,TGF-β1,the quality of life score and symptom score before and after oral Changlekang.Methods:1.According to the inclusion criteria,exclusion criteria and exit criteria,20 patients in the study group and 20 patients the control group were enrolled.The study group was given changlekang,Desloratadine Citrate Disodium Tablets and mometasone furoate nasal spray for treatment.After 2 weeks of treatment,Changlekang was still given for maintenance therapy for 6 weeks,and no other two kinds of drugs.The control group was given the Desloratadine Citrate Disodium Tablets and mometasone furoate nasal spray for 2 weeks and then quited the clinical trials.2.We collected the serum of patients in the study group and the control group before treatment,after 2 weeks of treatment,after the end of treatment,and got everyone’s symptom score and quality of life score at the same time,by means of four points,visual analogue scale,RQLQ.Moreover the serum of 10 healthy adults were collected as normal group.Enzyme linked immunosorbent assay was used to detect the levels of IL-10,TGF-beta 1 in each stage of each group in the three groups.3.Statistical analysis:(1)If the serum IL-10,TGF-beta,symptom score,total score of RQLQ of the study group patients had statistical difference during before treatment,after 2 weeks of treatment,after the end of treatment;(2)If there were statistical difference between the study group and the control group after 2 weeks’ treatment in serum IL-10,TGF-β1,symptom score,total score of RQLQ;(3)The correlation of serum IL-10 and TGF-β1 with symptom score and total score of RQLQ were analyzed.Results:1.Before treatment,serum TGF-β1 and IL-10 of normal group was significantly different from the study group and the control group(P < 0.001),and the study group and the control group’s were significantly lower than normal group;2.With the increase of treatment time,serum IL-10,TGF-β1 levels of patients in the study group increased gradually(after 8 weeks of treatment>after 2 weeks of treatment>before treatment).Four point method ocular symptoms score,VAS ocular symptoms score and total score of RQLQ decreased gradually(after 8 weeks of treatment<after 2weeks of treatment<before treatment);3.patients in the control group after 2 weeks’ treatment,serum IL-10,TGF-β1 was higher than that before treatment(P < 0.001),at the same time all symptom scores,total score of RQLQ were lower than those before treatment(P < 0.001).4.After 2 weeks’ treatment,patients in the study group,the serum IL-10 is higher than that of control group(P < 0.001),but there were no significant differences between the two groups of TGF-β1,symptoms and quality of life score(P > 0.05);5.Before treatment serum IL-10,TGF-β1 of AR patients might have little correlation with symptom scores,total score of RQLQ on linear(P > 0.05).Conclusion:1.serum IL-10,TGF-β1 levels of AR patients may be lower than normal,and IL-10TGF-β1 may be involved in the pathogenesis of AR;2.Combined Clostridium and Bifidobacterium Capsules,Live may increase the production of serum IL-10,TGF-β1 in AR patients;3.Combined desloratadine citrate with mometasone furoate nasal spray for treatment may increase the production of serum IL-10,TGF-β1 in AR patients;4.AR patients with desloratadine citrate and mometasone furoate nasal spray treatment combined with Combined Clostridium and Bifidobacterium Capsules,Live may promote higher serum IL-10 production than conventional two combination therapy,but there is no more significant improvement in symptoms score and quality of life score.5.Combined Clostridium and Bifidobacterium Capsules,Live may improve ocular symptoms and the quality of life in AR patients.6.Before treatment serum IL-10,TGF-β1 of AR patients may have little correlation with symptom scores,total score of RQLQ,as a result the level of serum IL-10 and TGF-β1 can not be used to evaluate the severity of AR for the time being. |